Mel Symeonides

@msymeonides.bsky.social

Assistant Prof at the University of Vermont, interested in HIV latency, syncytia, placenta etc. Opinions = my own.

How HIV research drives health innovation in multiple diseases The future of HIV research — and of the USA’s scientific leadership — depends on bold, sustained action in defense of discovery, investment, and innovation. www.nature.com/artic... 1/2

How HIV research drives health innovation in multiple diseases | Nature Medicine

The future of HIV research — and of the USA’s scientific leadership — depends on bold, sustained action in defense of discovery, investment, and innovation.

nature.com

What if the indirect cost model is truly broken and wasteful... AND the idea that it would be cut to 15% across the board with 3 days' notice is just about the worst way possible to address this problem?

Quoting this paper: Viral rebound has also been described in untreated individuals (24, 25), but often at a lower frequency compared with N-R treated individuals regardless of rebound definition (6, 17, 19, 20, 22, 23, 26, 27).

TThelonevirologist @thelonevirologist.bsky.social · last yr.

Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance journals.asm.org/doi/10.1128/...